JCO Precision Oncology, Journal Year: 2024, Volume and Issue: 8
Published: Oct. 1, 2024
PURPOSE Precision oncology relies on accurate and interpretable reporting of testing mutation rates. Focusing the BRAFV600 mutations in advanced colorectal carcinoma, non–small-cell lung cutaneous melanoma, we developed a platform displaying rates reported literature, which annotated using an artificial intelligence (AI) natural language processing (NLP) pipeline. METHODS Using AI, identified publications that likely or rate, filtered for cancer type, sentences Rates covariates were subsequently manually curated by three experts. The AI performance was evaluated precision recall metrics. We used interactive to explore present certain study characteristics. RESULTS dashboard, accessible at BRAF dimensions website, enables users filter with relevant options (eg, country study, type) visualize pipeline demonstrated excellent filtering (>90% all target types) moderate sentence classification (53%-99% precision; ≥75% recall). manual annotation revealed inter-rater disagreement (testing 19%; 70%), indicating unclear nonstandard some publications. CONCLUSION Our AI-driven NLP potential annotating biomarker difficulties encountered highlight need more AI-powered literature searching data extraction, consistent These improvements would reduce risk misinterpretation misunderstanding AI-based technologies health care community, beneficial impacts clinical decision-making, research, trial design.
Language: Английский